Company | Date | Price Target | Rating | Analyst |
---|---|---|---|---|
3/22/2024 | Buy → Hold | Argus | ||
3/8/2024 | $14.00 | Underweight → Neutral | JP Morgan | |
2/23/2024 | $36.00 | Buy | Guggenheim | |
2/12/2024 | $12.00 → $19.00 | Neutral → Overweight | Piper Sandler | |
1/23/2024 | $10.00 → $14.00 | Hold → Buy | Jefferies | |
1/4/2024 | $32.00 | Outperform → Market Perform | TD Cowen | |
1/3/2024 | $8.00 → $12.00 | Underweight → Neutral | Piper Sandler | |
12/18/2023 | $13.00 | Buy | HSBC Securities |
8-K - PFIZER INC (0000078003) (Filer)
RW - AGILE THERAPEUTICS INC (0001261249) (Filer)
8-K - Dare Bioscience, Inc. (0001401914) (Filer)
8-K - Evofem Biosciences, Inc. (0001618835) (Filer)
DEFA14A - AGILE THERAPEUTICS INC (0001261249) (Filer)
8-K - AGILE THERAPEUTICS INC (0001261249) (Filer)
8-K - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Filer)
S-1 - AGILE THERAPEUTICS INC (0001261249) (Filer)
11-K - PFIZER INC (0000078003) (Filer)
11-K - PFIZER INC (0000078003) (Filer)
Argus downgraded Pfizer from Buy to Hold
JP Morgan upgraded Teva Pharma from Underweight to Neutral and set a new price target of $14.00
Guggenheim initiated coverage of Pfizer with a rating of Buy and set a new price target of $36.00
Piper Sandler upgraded Teva Pharma from Neutral to Overweight and set a new price target of $19.00 from $12.00 previously
Jefferies upgraded Teva Pharma from Hold to Buy and set a new price target of $14.00 from $10.00 previously
TD Cowen downgraded Pfizer from Outperform to Market Perform and set a new price target of $32.00
Piper Sandler upgraded Teva Pharma from Underweight to Neutral and set a new price target of $12.00 from $8.00 previously
HSBC Securities initiated coverage of Teva Pharma with a rating of Buy and set a new price target of $13.00
UBS upgraded Teva Pharma from Neutral to Buy and set a new price target of $13.00 from $11.00 previously
UBS resumed coverage of Pfizer with a rating of Neutral and set a new price target of $34.00 from $36.00 previously
SC 13G - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)
SC 13G/A - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G/A - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G/A - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)
SC 13G/A - AGILE THERAPEUTICS INC (0001261249) (Subject)
SC 13G/A - Evofem Biosciences, Inc. (0001618835) (Subject)
SC 13G/A - AGILE THERAPEUTICS INC (0001261249) (Subject)
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website. About Teva Teva Pharmac
Board of Directors approves quarterly cash dividend of $0.42 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.42 third-quarter 2024 dividend on the company's common stock, payable September 3, 2024, to holders of the Common Stock of record at the close of business on July 26, 2024. The third-quarter 2024 cash dividend will be the 343rd consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery,
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the "ITA") resolving all pending litigation with respect to taxes payable for the Company's taxable years 2008-2020. Under the terms of the agreement the Company will pay a total of $750 million in installments between 2024 to 2029. This allows Teva to end this historical income tax issue, and to continue to focus on its commitment to the health of patients and on the continued implementation of its "Pivot to Growth" strategy. Under the terms of the agreement, it was further agreed that in the future event Teva pays dividends on, or repurchases, its e
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:30 a.m. EDT on Tuesday, July 30, 2024. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2024 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the conferen
First Quarter Net Revenue Increased 58% and Factory Sales Increased 3% from Fourth Quarter 2023 Twirla First Quarter 2024 Demand Rebounded 18% from Fourth Quarter 2023 PRINCETON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (OTC:AGRX), a women's healthcare company, today reported financial results for the three months ended March 31, 2024 and provided a corporate update. "We are excited about the start of 2024, which saw a rebound in demand, factory sales and net sales in the first quarter from our fourth quarter 2023 results. We plan to continue to focus on executing our business plan, which we believe can continue to grow Twirla and enable us to manage our ope
SAN DIEGO, May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate), Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced financial results for the first quarter of 2024. Highlights of and since the quarter include: EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Women's health innovator Evofem Biosciences (OTCQB:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Received $1 million from Aditxt, Inc. (NASDAQ:ADTX) in May 2024 in consideration for reinstating and amending
Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United StatesSildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder successful completion of end-of-Phase 2 meeting with FDA; forthcoming additional FDA feedback; Phase 3 design, development, and collaboration strategy updates SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, today reported financial results for the quarter ended March 31, 2024
For an accessible version of this Press Release, please visit www.tevapharm.com Generics business and AUSTEDO® growth lead Q1 2024 performance. Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. Generics business growth across all regions – increased by 9% in local currency terms globally, compared to Q1 2023. AUSTEDO – continued growth, up 67% (in the U.S.) from Q1 2023; reaffirming 2024 revenue outlook of ~$1.5 billion. AJOVY® – revenues of $113 million in Q1 2024, up 18% from Q1 2023. Recent FDA approvals of SIMLANDI® and SELARSDI™, biosimilars to Humira® and Stelara®, respectively. Announced positive Phase 3 effi
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 14, 2024, to review its financial results for the quarter ended March 31, 2024 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll free). The conference ID number for the call is 5582540. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior t
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webcast will be available within 24 hours after the end of the live discussion and will be accessible for up to 90 days. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a c
Novo Nordisk A/S (NYSE:NVO), the maker of the popular obesity drug Ozempic, has been reprimanded by the U.K.’s Prescription Medicines Code of Practice Authority (PMCPA) for failing to disclose fees and expenses paid to individuals and organizations in Britain of approximately 7.8 million pounds (around $10 million) between 2020 and 2022. On Friday, the U.K. industry body PMCPA announced that the reprimand followed a voluntary submission by Novo Nordisk regarding these payments. Also Read: Joe Biden Suggests Novo Nordisk, Eli Lilly To Lower Prices For Its Popular Obesity Drugs. The PMCPA stated that the payments involved over 150 bodies, including fees and expenses to health professi
https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-evaluate-potential-risk-neural-tube-birth-defects-hiv-medicine
https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-evaluate-potential-risk-neural-tube-birth-defects-hiv-medicine?Fri,%2005%20Jul%202024%2010:30:16%20EDT
Financial giants have made a conspicuous bearish move on Pfizer. Our analysis of options history for Pfizer (NYSE:PFE) revealed 8 unusual trades. Delving into the details, we found 37% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $184,039, and 4 were calls, valued at $142,082. Projected Price Targets After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $22.5 and $35.0 for Pfizer, spanning the last three months. Insights into Volume & Open Interest Looking at the volume and open interest is an insightful way to conduct due diligence
Wednesday, GSK plc (NYSE:GSK) and CureVac N.V. (NASDAQ:CVAC) announced they have restructured their existing collaboration into a new licensing agreement, allowing the companies to prioritize investment and focus on its respective mRNA development activities. Since 2020, GSK and CureVac have worked together to develop mRNA vaccines for infectious diseases. Through this collaboration, GSK and CureVac have vaccine candidates for seasonal influenza and COVID-19 in Phase 2 and avian influenza in Phase 1 clinical development. All candidates are based on CureVac's proprietary second-generation mRNA backbone. Also Read: CureVac, GSK Partner Release Data On Influenza Vaccine Study. GS
Pfizer Inc. (NYSE:PFE) and Moderna Inc. (NASDAQ:MRNA) are set for more legal battles over their rival COVID-19 vaccines after London’s High Court delivered a mixed ruling on two of Moderna’s patents. This decision is likely to trigger a series of appeals in the ongoing London litigation. Pfizer and its German partner BioNTech SE (NASDAQ:BNTX) initiated the lawsuit against Moderna in London in September 2022, seeking to revoke two of Moderna’s patents. In response, Moderna accused Pfizer and BioNTech of infringing on its patents. These lawsuits are part of a global legal struggle over messenger RNA (mRNA) technology. Read Next: European Patent Office Sides with Moderna In COVID-19
A Delaware judge has dismissed a request from GSK Plc (NYSE:GSK) and other pharmaceutical companies to appeal a ruling that allows over 70,000 lawsuits alleging the heartburn drug Zantac causes cancer to proceed. This ruling, made by Judge Vivian Medinilla of the Delaware Superior Court, means the drugmakers—Pfizer Inc (NYSE:PFE), Sanofi SA (NASDAQ:SNY), and Boehringer Ingelheim—must seek permission directly from the Delaware Supreme Court to appeal. GSK confirmed it has already submitted its appeal. Also Read: Pfizer Agrees To Settle Over 10,000 Lawsuits About Cancer Risks Associated With Discontinued Heartburn Drug Zantac. If the state high court rejects the appeal, the Zantac law
Amazon.com Inc (NASDAQ:AMZN) is taking an all-encompassing approach to enterprise AI in an effort to better deliver the tools that customers need when they need them. What To Know: Monday on CNBC’s “Closing Bell: Overtime,” Amazon Web Services (AWS) CEO Matt Garman stressed that there is so much more to AI than the chatbots which get most of the attention. “It’s not just one application, it’s not just a chatbot that you can put on your website and have talk to your customers, which is a very cool application by the way, but many customers if they stop there, they’re not going to get the true value out of what this technology is bringing to them,” Garman said. Amazon offers much mor
The Federal Trade Commission (FTC) has initiated an investigation into Teva Pharmaceutical Industries Ltd (NYSE:TEVA) over its refusal to remove about two dozen patents for its asthma and COPD inhalers. This move comes amid accusations that Teva has engaged in practices to maintain market exclusivity and block generic competition. Related: Federal Trade Commission Targets’ Junk Patent Listings’ For Diabetes, Weight Loss, Asthma Drugs From Companies Like Novo Nordisk, AstraZeneca. Confidential agency documents reviewed by The Washington Post revealed that the FTC last week issued a civil investigative demand, effectively a subpoena, to Teva. This demand compels the company to prov
9 analysts have expressed a variety of opinions on Pfizer (NYSE:PFE) over the past quarter, offering a diverse set of opinions from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 8 1 0 0 Last 30D 0 1 0 0 0 1M Ago 0 3 0 0 0 2M Ago 0 1 1 0 0 3M Ago 0 3 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.22, a high estimate of $45.00, and a low estimate of $29.00. This upward trend is apparent, with the current ave
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website. About Teva Teva Pharmac
Pfizer Inc. (NYSE:PFE) today announced the election of Cyrus Taraporevala to its Board of Directors, effective immediately. Mr. Taraporevala, age 57, was also appointed to and will join the Audit Committee and Compensation Committee of Pfizer's Board. Mr. Taraporevala served as President and Chief Executive Officer at State Street Global Advisors from 2017 until his retirement in 2022. Prior to joining State Street, he held numerous leadership roles in asset management, including at Fidelity, BNY Mellon, Legg Mason, and Citigroup. Earlier in his career, Mr. Taraporevala was a partner at McKinsey & Company, based in New York and Copenhagen. He serves on the boards of directors of Shell p
4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki New sub-analysis of PEARL data highlights potential negative impact of treatment pauses on patient outcomes1 Sub-analysis exploring impact of treatment cessation and reinitiation on migraine prevention suggests potential rise in migraine attacks and diminished treatment effectiveness upon reinitiation1 Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announces new data from the 4th interim analysis of the PEARL migraine prevention study with AJOVY® (fremanezumab) that may challenge the rationale for treatment pauses with c
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineagesDoses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission NEW YORK and MAINZ, Germany, June 27, 2024 — Pfizer Inc. (NYSE:PFE, "Pfizer"))) and BioNTech SE (NASDAQ:BNTX, "BioNTech"))) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Age
— Leading telemedicine company expands offering with hormone-free birth control as GLP-1 medication usage increases — — Hello Alpha partnership boosts awareness of and access to Phexxi for millions of women — SAN DIEGO, June 27, 2024 /PRNewswire/ -- Women's health innovator Evofem Biosciences, Inc. (OTCQB:EVFM) today announced a new market partnership with Hello Alpha, a telemedicine company with a medical team specifically trained for a woman's unique needs, to offer Phexxi® (lactic acid, citric acid and potassium bitartrate), the non-hormonal prescription vaginal gel FDA-approved to prevent pregnancy for those who choose to use an on-demand method of birth control.
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, today announced that it will implement a 1-for-12 reverse split of the issued shares of its common stock, effective at 12:01 a.m. Eastern Time on July 1, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Monday, July 1, 2024, and will continue to trade on The Nasdaq Capital Market under the symbol "DARE." The new CUSIP number for the common stock will be 23666P200. The reverse stock split is intended to increase
Board of Directors approves quarterly cash dividend of $0.42 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.42 third-quarter 2024 dividend on the company's common stock, payable September 3, 2024, to holders of the Common Stock of record at the close of business on July 26, 2024. The third-quarter 2024 cash dividend will be the 343rd consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery,
Agile Therapeutics will combine with Insud Pharma's US Subsidiary, Exeltis, expanding an already significant Women's Health/contraceptive portfolio Agile Therapeutics Common Shareholders expected to receive $1.52 per share of common stock – approximately a 356% premium to the closing share price on June 25, 2024 Definitive Merger Agreement is subject to Agile Shareholder Approval. Agile Board is recommending shareholder approval of the Definitive Merger Agreement PRINCETON, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. ("Agile") (OTCQB:AGRX), a women's healthcare company, today announced that it has entered into a definitive merger agreement ("Merger Agreement") with
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the "ITA") resolving all pending litigation with respect to taxes payable for the Company's taxable years 2008-2020. Under the terms of the agreement the Company will pay a total of $750 million in installments between 2024 to 2029. This allows Teva to end this historical income tax issue, and to continue to focus on its commitment to the health of patients and on the continued implementation of its "Pivot to Growth" strategy. Under the terms of the agreement, it was further agreed that in the future event Teva pays dividends on, or repurchases, its e
Generic Victoza® is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market. This launch adds to Teva's continued commitment to its complex generic medicine portfolio. Liraglutide injection is indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus and reduce the risk of cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease. Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of an authorized generic of Victoza®1 (liraglutide injectio
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
3 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company's manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé, who is leaving after 11 years with the Company, including more than four years as Executive Vice President, Global Operations. Mr. Shields will be a member of Teva's Executive Leadership Team and report directly to President and CEO Richard Francis. He will be based in Teva's U.S. headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2
HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager. Mr. Barnum will oversee the process management, quality, and operations of ALTIVIA's Specialty and Oxide Chemicals' units. Mr. Hale will lead the development and management of ALTIVIA's Corporate Engineering Department. "We look forward to welcoming both Scott and Dean as ALTIVIA furthers its investment in growth, sustainability, and world-class operating performance," said Michael Jusbasche, ALTIVIA's Chief
Pfizer Inc. (NYSE:PFE) invites investors and the general public to access a live video webcast of its Oncology Innovation Day on Thursday, February 29, 2024, from 1:00 p.m. EST to 5:30 p.m. EST, with an approximately 20-minute break at the midpoint. During the event, Pfizer Oncology leadership will provide details on the new combined Pfizer Oncology Division, including its strategic approach, robust portfolio, industry-leading R&D capabilities and potential for growth through 2030 and beyond. To access the live webcast and presentation slides, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/invest
SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors to better reflect the Company's size following the voluntary resignations of Cheryl R. Blanchard, Ph.D. and Sophia Ononye-Onyia, Ph.D. "On behalf of the Daré team, I am so grateful to Lisa and Joh
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Richard Francis, Teva's President and CEO said: "I am excited to welcome Ananth back to Teva to lead the Teva api business during this pivotal time for our company, as we continue to progress on our plan for turning Teva api into a standalone business. We're confident that this strategy will result in a more focused end-to-end operation, and I am confident tha
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene Therapies at Novartis will be the new head of Teva's U.S. Commercial Business. "On behalf of the Teva Board of Directors and our executive management team, I want to thank Sven for his many contributions to Teva during his 15 years with the company," said Richard Francis, Teva's President, and Chief Executive Officer, "I am pleased to announce the appointment of Chris Fox to this critical role. Chris is a h
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. Angus Grant, Ph.D., as EVP, Business Development. Dr. Grant will begin his employment on August 1, 2023, and will be based out of Teva's US headquarters in Parsippany, NJ. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230727524382/en/(Photo: Business Wire) Dr. Grant joins Teva with over 25 years of experience in the global pharmaceutical and biotech industry, with an exceptional track record across a variety of fields including Business Development, R&D and Regulatory Affairs. Most recently, Dr. Grant served as the Chief Business Ex
Sath Shukla, current Spero Chief Financial Officer, will bring more than 20 years of strategic and financial leadership to the role of CEO, to be effective August 1, 2023 Current President and Chief Executive Officer, Ankit Mahadevia, M.D to become Chairman of the Board of Directors CAMBRIDGE, Mass., June 14, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (NASDAQ:SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Satyavrat "Sath" Shukla, Spero's current Chief Financial Officer and Treas
SAN DIEGO, April 14, 2023 /PRNewswire/ -- Evofem Biosciences, Inc., (OTCQB:EVFM), the maker of Phexxi® (lactic acid, citric acid and potassium bitartrate), today announced the appointment of Ivy Zhang as Chief Financial Officer (CFO) and Secretary, effective April 13, 2023. Reporting to Chief Executive Officer Saundra Pelletier, Ms. Zhang will lead Evofem's finance organization and financial activities including financial planning and analysis, accounting, external audit, tax, controllership, and treasury functions. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Bioscien
SAN DIEGO, March 9, 2023 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB:EVFM) is pleased to announce the appointment of Albert Altro as Interim Chief Financial Officer of the Company. He replaces Jay File, who is leaving the Company to explore other opportunities. EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)" alt="Evofem Biosciences (NASDAQ:EVFM) (PRNewsfoto/Evofem Biosciences, Inc.)"> Mr. Altro brings over 25 years of financial and operational experience including corporate restructuring, public accounting and executive management, and consulting, primarily in a leadership rol
Submission status for PFIZER INC's drug NICOTROL (SUPPL-12) with active ingredient NICOTINE has changed to 'Approval' on 05/23/2024. Application Category: NDA, Application Number: 020385, Application Classification: Labeling
Submission status for PFIZER INC's drug TALZENNA (ORIG-1) with active ingredient TALAZOPARIB has changed to 'Approval' on 03/07/2024. Application Category: NDA, Application Number: 217439, Application Classification: Type 5 - New Formulation or New Manufacturer
Submission status for PFIZER INC's drug IXIFI (SUPPL-9) with active ingredient INFLIXIMAB-QBTX has changed to 'Approval' on 12/26/2023. Application Category: BLA, Application Number: 761072, Application Classification:
Submission status for PFIZER INC's drug ELREXFIO (SUPPL-1) with active ingredient ELRANATAMAB has changed to 'Approval' on 12/13/2023. Application Category: BLA, Application Number: 761345, Application Classification:
Submission status for PFIZER INC's drug RUXIENCE (SUPPL-11) with active ingredient RITUXIMAB-PVVR has changed to 'Approval' on 10/16/2023. Application Category: BLA, Application Number: 761103, Application Classification:
Submission status for PFIZER INC's drug VELSIPITY (ORIG-1) with active ingredient ETRASIMOD has changed to 'Approval' on 10/12/2023. Application Category: NDA, Application Number: 216956, Application Classification: Type 1 - New Molecular Entity
Submission status for PFIZER INC's drug ABRILADA (SUPPL-7) with active ingredient ADALIMUMAB-AFZB has changed to 'Approval' on 10/04/2023. Application Category: BLA, Application Number: 761118, Application Classification:
For Immediate Release: October 03, 2023 Today, the U.S. Food and Drug Administration amended the emergency use authorization (EUA) of the Novavax COVID-19 Vaccine, Adjuvanted for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years of age and older previously vaccinated with a COVID-19 vaccine (and who have not already been vaccinated with a recently updated mRNA CO
For Immediate Release: September 11, 2023 Today, the U.S. Food and Drug Administration took action approving and authorizing for emergency use updated COVID-19 vaccines formulated to more closely target currently circulating variants and to provide better protection against serious consequences of COVID-19, including hospitalization and death. Today’s actions relate to updated mRNA vaccines for 2023-2024 manufac
For Immediate Release: August 21, 2023 Today, the U.S. Food and Drug Administration approved Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age. Abrysvo is approved for use at 32 through 36 weeks gestatio